Third Opinion Trial Synopsis
Doctors will give a new medicine called daratumumab to patients with a type of cancer called multiple myeloma. They will also give them three other medicines called clarithromycin, pomalidomide, and dexamethasone, and keep giving it until the cancer gets worse or there are bad side effects. The doctors want to see if this new combination of medicines will work better than the old treatment. They hope it will make the cancer get better more than it did before.

Trial Summary
This is a single-center, non-randomized, phase 2 study in which patients will receive daratumumab (subcutaneous, SC) in combination with clarithromycin/pomalidomide/dexamethasone (D-ClaPd) until progressive disease (PD) or unacceptable toxicity. This study will test the hypothesis that in patients with previous daratumumab exposure, combination therapy of clarithromycin/pomalidomide/dexamethasone with daratumumab SC (D-ClaPd) will yield higher Very Good Partial Response (VGPR) rates in relapsed/refractory multiple myeloma patients than historical pomalidomide/dexamethasone treatment.